Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas-Reference-Cited by-同舟云学术

Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas

Published:2005-08 Issue: Volume:356 Page:109-117
ISSN:0378-1119
Container-title:Gene
language:en
Short-container-title:Gene

Author:

Gunduz Mehmet,Nagatsuka Hitoshi,Demircan Kadir,Gunduz Esra,Cengiz Beyhan,Ouchida Mamoru,Tsujigiwa Hidetsugu,Yamachika Eiki,Fukushima Kunihiro,Beder Levent,Hirohata Satoshi,Ninomiya Yoshifumi,Nishizaki Kazunori,Shimizu Kenji,Nagai Noriyuki

Publisher

Elsevier BV

Subject

Genetics,General Medicine

Reference28 articles.

1. Prognostic value of genomic alterations in head and neck squamous cell carcinoma detected by comparative genomic hybridisation;Ashman;Br. J. Cancer,2003

2. Haploinsufficiency of p18 (INK4c) sensitizes mice to carcinogen-induced tumorigenesis;Bai;Mol. Cell. Biol.,2003

3. Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas;Beder;Lab. Invest.,2003

4. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma;Cote;J. Natl. Cancer Inst.,1998

5. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control;Garkavtsev;Nature,1998

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms of inhibitor of growth (ING) family members in health and malignancy;Cancer Cell International;2022-09-02

2. A Novel Splice Variant of the Inhibitor of Growth 3 Lacks the Plant Homeodomain and Regulates Epithelial–Mesenchymal Transition in Prostate Cancer Cells;Biomolecules;2021-08-04

3. ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer;Clinical Breast Cancer;2021-08

4. ING3 and ING4 immunoexpression and their relation to the development of benign odontogenic lesions;Brazilian Dental Journal;2021-08

5. Current paradigms in epigenetic anticancer therapeutics and future challenges;Seminars in Cancer Biology;2021-03